✦ LIBER ✦

Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies

✍ Scribed by Irwin, David J.; Lee, Virginia M.-Y.; Trojanowski, John Q.

Book ID: 120627702
Publisher: Nature Publishing Group
Year: 2013
Tongue: English
Weight: 728 KB
Volume: 14
Category: Article
ISSN: 1471-0048
DOI: 10.1038/nrn3549

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Parkinson's disease dementia: at the cro

Parkinson's disease dementia: at the crossroads of α-synuclein, tau and amyloid-β

✍ Irwin, David; Lee, V.; Trojanowski, J. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 49 KB

CSF α-synuclein, tau, and amyloid β in P

CSF α-synuclein, tau, and amyloid β in Parkinson's disease

✍ Min Shi; Jing Zhang 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 36 KB

The Significance of a-Synuclein, Amyloid

The Significance of a-Synuclein, Amyloid-� and Tau Pathologies in Parkinson's Disease Progression and Related Dementia

✍ Compta, Yaroslau; Parkkinen, Laura; Kempster, Peter; Selikhova, Mariana; Lashley 📂 Article 📅 2013 🏛 S. Karger AG 🌐 English ⚖ 61 KB

CSF α-synuclein, tau, and amyloid β in P

CSF α-synuclein, tau, and amyloid β in Parkinson's disease – Authors' reply

✍ Brit Mollenhauer; Walter J Schulz-Schaeffer; Michael G Schlossmacher 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 45 KB

Tau and α-synuclein in susceptibility to

Tau and α-synuclein in susceptibility to, and dementia in, Parkinson's disease

✍ An Goris; Caroline H. Williams-Gray; Graeme R. Clark; Thomas Foltynie; Simon J. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 1 views

Cerebrospinal fluid Tau/α-synuclein rati

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

✍ Lucilla Parnetti; Davide Chiasserini; Gianni Bellomo; David Giannandrea; Claudia 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 484 KB

## Abstract Although alpha‐synuclein is the main constituent of Lewy bodies, cerebrospinal fluid determination on its own does not seem fundamental for the diagnosis of synucleinopathies. We evaluated whether the combination of classical biomarkers, Aβ~1–42~, total tau, phosphorylated tau, and α‐sy